Topics

Vaccines

Moderna spars with US scientists over COVID-19 vaccine trials

Exclusive: Moderna spars with U.S. scientists over COVID-19 vaccine trials

By: Marisa Taylor and Robin Respaut
Source: Reuters
Date of Publication: July 7th, 2020
As the United States accelerates the search for a coronavirus vaccine, tensions have erupted between government scientists and Moderna Inc, one of the leading developers, Reuters has learned.
U.S. signs $450 million contract with Regeneron for COVID-19 therapy

U.S. signs $450 million contract with Regeneron for COVID-19 therapy

By: Manojna Maddipatla
Source: Reuters
Date of Publication: July 7th, 2020
The U.S. government signed a $450 million contract with Regeneron Pharmaceuticals Inc (REGN.O) for its potential COVID-19 antibody cocktail, the drugmaker said on Tuesday.
U.S. government awards Novavax $1.6 billion for coronavirus vaccine

U.S. government awards Novavax $1.6 billion for coronavirus vaccine

By: Julie Steenhuysen
Source: Reuters
Date of Publication: July 7th, 2020
The U.S. government has awarded Novavax Inc $1.6 billion to cover testing, commercialization and manufacturing of a potential coronavirus vaccine in the United States, with the aim of delivering 100 million doses by January 2021.
Pfizer reports encouraging early covid-19 vaccine data

Pfizer reports encouraging early coronavirus vaccine data

By: Carolyn Y. Johnson
Source: The Washington Post
Date of Publication: July 1st, 2020
In a small trial, an experimental vaccine triggered immune responses similar to those in recovered patients.
Regeneron Begins Testing Coronavirus Antibody Cocktail Therapy - WSJ

Regeneron Begins Testing Coronavirus Antibody Cocktail Therapy

By: Jonathan D. Rockoff
Source: The Wall Street Journal
Date of Publication: June 11th, 2020
If the drug proves to work safely, it could be available for emergency use as early as the fall, company says.
Gilead’s next COVID-19 treatment advancement could keep patients out of hospitals

Gilead’s next COVID-19 treatment advancement could keep patients out of hospitals

By: Sy Mukherjee
Source: Fortune
Date of Publication: June 22nd, 2020
Gilead won the first Food and Drug Administration (FDA) emergency authorization for a COVID-19 treatment in May. Now, the biotech giant says, it will soon begin clinical trials for a different version of the same experimental drug, remdesivir, which might make it easier to administer outside of a hospital or ICU wing.
Coronavirus pandemic threatens to delay potentially life-changing, new medicines

Coronavirus pandemic threatens to delay potentially life-changing, new medicines

By: Berkeley Lovelace Jr.
Source: CNBC
Date of Publication: June 19th, 2020
The coronavirus pandemic postponed the start of clinical trials for potentially life-changing, new medicines. It also could delay the time in which some of those drugs will reach the market as the U.S. Food and Drug Administration faces a potential surge in applications amid a pandemic. The full impact of the postponements for testing new drugs, treatments and vaccines for ailments besides Covid-19 may not be known for months.
CORRECTED-Mastercard to allow staff to work from home until COVID-19 vaccine hits market - exec_Reuters

CORRECTED-Mastercard to allow staff to work from home until COVID-19 vaccine hits market - exec

By: Noor Zainab Hussain
Source: Reuters
Date of Publication: May 20th, 2020
Mastercard Inc will not ask staff to return to its worldwide corporate offices until a vaccine is available for the sometimes fatal coronavirus that has infected the globe, a senior executive told Reuters on Wednesday.
Exclusive_ Lilly COVID-19 treatment could be authorized for use as soon as September - chief scientist

Exclusive: Lilly COVID-19 treatment could be authorized for use as soon as September - chief scientist

By: Carl O'Donnell and Michael Erman
Source: Reuters
Date of Publication: June 10th, 2020
Eli Lilly and Co could have a drug specifically designed to treat COVID-19 authorized for use as early as September if all goes well with either of two antibody therapies it is testing, its chief scientist told Reuters on Wednesday.
BIO_ Moderna, Merck execs see possible speed bumps in COVID-19 vaccine manufacturing _ FiercePharma

BIO: Moderna, Merck execs see possible speed bumps in COVID-19 vaccine manufacturing

By: Eric Sagonowsky
Source: FiercePharma
Date of Publication: June 11th, 2020
The companies will have to overcome many obstacles to quickly produce a COVID-19 vaccine.